Nothing Special   »   [go: up one dir, main page]

Ellis et al., 2023 - Google Patents

Complete Synthesis and Stereochemical Assignment of Novel Curcuphenol Analogues Possessing Anti-Metastatic Cancer Biological Activity

Ellis et al., 2023

View PDF
Document ID
15031393964852693888
Author
Ellis S
Nohara L
Dada S
Saranchova I
Munro L
Choi K
Garrovillas E
Pfeifer C
Williams D
Cheng P
Andersen R
Jefferies W
Publication year
Publication venue
bioRxiv

External Links

Snippet

For eons, turmeric and curcumin have been used as culinary spices and as traditional medicines and as vogue dietary supplements for a growing list of disorders, including arthritis, digestive disorders, respiratory infections, allergies, liver disease, depression and …
Continue reading at www.biorxiv.org (PDF) (other versions)

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICRO-ORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICRO-ORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives
    • A61K47/48—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives the non-active ingredient being chemically bound to the active ingredient, e.g. polymer drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICRO-ORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICRO-ORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues ; Not used, see subgroups

Similar Documents

Publication Publication Date Title
Huber et al. Cancer acidity: An ultimate frontier of tumor immune escape and a novel target of immunomodulation
Verbeke et al. Broadening the message: a nanovaccine co-loaded with messenger RNA and α-GalCer induces antitumor immunity through conventional and natural killer T cells
CN107921111B (en) Novel peptides, peptide compositions and scaffolds for immunotherapy of various cancers
US20210085721A1 (en) Compositions and methods for the treatment of cancer using a cd8 engineered t cell therapy
JP6899333B2 (en) General-purpose killer T cells
CN108026154B (en) Novel peptides and peptide compositions for immunotherapy of ovarian and other cancers
Draghiciu et al. Sunitinib depletes myeloid-derived suppressor cells and synergizes with a cancer vaccine to enhance antigen-specific immune responses and tumor eradication
Tian et al. 5‐Fluorouracil efficacy requires anti‐tumor immunity triggered by cancer‐cell‐intrinsic STING
Serafini Myeloid derived suppressor cells in physiological and pathological conditions: the good, the bad, and the ugly
US11369668B1 (en) Tumor cell vaccines
CN113480604A (en) Novel peptides and peptide compositions for immunotherapy of ovarian and other cancers
CN111201032B (en) Small-sized group sequence variant of tumor-associated antigen epitope
ES2826480T3 (en) Methods to predict the usefulness of neoantigens for immunotherapy
Cochran et al. Extracellular vesicles from the human natural killer cell line NK3. 3 have broad and potent anti-tumor activity
JP2022130596A (en) MODIFIED NK-92 haNK003 CELLS FOR CLINIC
Matsuo et al. Recent progress in dendritic cell-based cancer immunotherapy
Galliverti et al. Myeloid cells orchestrate systemic immunosuppression, impairing the efficacy of immunotherapy against HPV+ cancers
JPWO2007097370A1 (en) Immunotherapy with target antigen and CD1d co-expressing cells pulsed with CD1d ligand
EP3468585A2 (en) Calr and jak2 vaccine compositions
CN115925806A (en) Novel peptides, peptide compositions and scaffolds for immunotherapy of various cancers
Zhao et al. Placenta-derived gp96 as a multivalent prophylactic cancer vaccine
Olin et al. Oxygen is a master regulator of the immunogenicity of primary human glioma cells
Wang et al. Naringenin enhances the antitumor effect of therapeutic vaccines by promoting antigen cross-presentation
Dada et al. Specific cannabinoids revive adaptive immunity by reversing immune evasion mechanisms in metastatic tumours
Rasoulouniriana et al. A distinct subset of FcγRI-expressing Th1 cells exert antibody-mediated cytotoxic activity